The universe of pharmaceutical trademarks in Russia 2021

5 minute read
07 April 2021


In this comprehensive report, now in its third edition, we present a detailed and current review of the trademark aspects of the pharmaceutical industry in Russia today – a market that Deloitte valued at almost US$30 billion in a recent study.

Russia's mandate to achieve innovative pharma industry

At an accelerating pace over the last decades, there has been a strong mandate to establish an effective and innovative pharma industry in Russia that will stand and succeed on its own. This has left multinational innovators wondering what long-term presence they could hope to have in Russia. Observers and participants see dynamic changes and long-ranging opportunities, but these are also weighed against a backdrop of possible further sanctions and counter-sanctions, Russian economic stagnation, and other challenges.

"Pharma 2020" plan aims to localize Russian pharmaceutical market

In 2009, the Russian government introduced its ambitious "Pharma 2020" plan to develop and foster innovation and the localization of the Russian pharmaceutical market. Among other things, this incentivized international pharma companies with long-term interests in Russia to localize production. It also clearly guided the market to reshape in favor of locally produced medicines.

Draft "Pharma 2030" launched to enhance localized and innovative programming

In 2018, Pharma 2020's successor, "Draft Pharma 2030," was unveiled, identifying key problems remaining in the industry, and pushing a still more aggressive localized and innovation program. It allocates funds for the further development of the Russian pharmaceutical sector, for example, not only for the localized production of the medicines themselves, but for every aspect of their manufacture.

COVID-19 has of course compounded the government's determination to push its localization agenda forward and to move quickly on many other health care-related initiatives, such as online pharmacies. Here, we examine where things now stand with Pharma 2020, as well as the ground being rapidly laid for Pharma 2030.  

Overview of guide

  • This review begins with an economic overview of the pharmaceutical industry in Russia and the drive for growing the market of locally produced medicines;
  • It then takes a detailed look at the legal foundations for the protection of trademarks in Russia, followed by a guide to recent decisions by Russia's IP Court and the RF Supreme Arbitration Court;
  • Next, it examines the counterfeit pharmaceuticals market, as well as of the ongoing anti-counterfeit effort to fight it; and
  • Finally, there is an analysis of the parallel importation of pharmaceuticals in Russia and concerns about what the possible legalization of parallel importation could mean for the pharma sector.

Download the guide

Download the comprehensive guide to pharmaceutical trademarks in Russia.

Sign up to receive email updates, event invitations, announcements, and other information and materials we think may interest you:

* Required

By signing up you agree to our terms of use, privacy statement and cookie policy. You can unsubscribe at any time.
Contact us |

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.